Genentech Emphasizes Personalized R&D Approach
This article was originally published in Pharmaceutical Approvals Monthly
Genentech is applying a personalized medicine approach to nearly all clinical development programs, CEO Arthur Levinson said Jan. 9
You may also be interested in...
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts